Plan-les-ouates, Switzerland
Plan-les-ouates, Switzerland

Time filter

Source Type

News Article | May 9, 2017
Site: globenewswire.com

Support Potential of ADX71441 to treat Irritable Bowel  Syndrome, Interstitial Cystitis and Painful Bladder Syndrome Geneva, Switzerland, 9 May 2017 - Addex Therapeutics (SIX: ADXN) announced today positive results from multiple preclinical studies of ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor, in models of visceral hyperalgesia. The studies were led by Prof. Jyoti N. Sengupta at the Medical College of Wisconsin, with the support of a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the US National Institute of Health. The findings strongly support the potential of ADX71441 in treating hyperalgesia in colonic inflammation (colitis) and bladder inflammation (cystitis). Chronic visceral pain syndromes related to the gastrointestinal or urinary tract represent an important unmet medical need as they can significantly impact the patient's quality of life. "These data represent an important step forward in the understanding of the role played by GABAB receptors in visceral pain and the potential of ADX71441 in large unmet medical needs, such as irritable bowel syndrome, interstitial cystitis and painful bladder syndrome," said Sonia Poli, CSO of Addex. "We look forward to continuing our collaboration with Prof Sengupta's group, and further evaluating the possibility of conducting clinical trials for ADX71441 in these compelling indications." The effect of ADX71441 was studied in reliable, reproducible and quantifiable preclinical models of visceral pain, which included behavioral measurements and electrophysiology recordings(1). Visceral motor reflex after colorectal distension (CRD) and urinary bladder distension (UBD) was significantly decreased (p<0.05) following systemic administration of ADX71441 (5, 10 and 50 mg/kg ip). The visceral analgesic effect of ADX71441 did not affect the normal function of the bladder as assessed by cystometry. In electrophysiology experiments, ADX71441 demonstrated significant inhibition of the response of UBD responsive lumbo-sacral (LS) spinal dorsal horn neurons to graded bladder distension. The effect was observed in spinal intact rats, but not in cervical (C1-C2) spinal transected rats. It also produced a moderate decrease in the spontaneous firing of these neurons in spinal intact rats. ADX71441 had no effect on the mechano-transduction properties or the spontaneous firing of UBD-sensitive pelvic nerve afferent (PNA) fibers. The current behavioral experiments to assess pain and the electrophysiology results indicate that ADX71441 produces visceral analgesia in animal models of cystitis and colitis.  The results indicate that ADX71441 produces this analgesic effect primarily by acting at the supra-spinal sites without affecting bladder motility. "We thank the NIDDK for their support and Prof. Sengupta and his team for their dedication to this important research with ADX71441," commented Tim Dyer, CEO of Addex. "These compelling results are a further example of how we are leveraging our collaborations with leading academic institutions to better understand the potential of the promising candidates in our pipeline." About GABA B receptor The GABAB receptor is clinically & commercially validated. Generic GABAB receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and French health authorities have approved its use for the treatment of alcoholism. Baclofen is also used off label for a number of other indications including overactive bladder (OAB), but its utility is limited due to variety of side effects and rapid clearance, requiring frequent administration of higher doses. About ADX71441 ADX71441 is a potent selective positive allosteric modulator (PAM) which potentiates GABA responses at the GABAB receptor. ADX71441 is a novel, first-in-class, oral, small molecule that demonstrated excellent preclinical efficacy and tolerability in rodent models of pain, anxiety, OAB, alcohol use disorders, nicotine dependence and in a non-human primate model of cocaine use disorder. ADX71441 has also proven efficacy in a genetic model of Charcot-Marie-Tooth Type 1A disease (CMT1A). ADX71441 has a different molecular mechanism from the generic drug baclofen in that it is a positive allosteric modulator, rather than an orthosteric agonist at the GABAB receptor, with a longer half-life, suitable for once daily administration. ADX71441 only acts when the natural ligand (GABA) activates the receptor, therefore respecting the physiological cycle of activation. It has been proposed that PAMs produce less adverse effects and lead to less tolerance than direct agonists. Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase 1 and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM, mGluR7NAM, TrkBPAM and mGluR3NAM & PAM. Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


— Pipeline report on Sickle Cell Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders). The complete is analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Browse the 54 Tables and 11 Figures, 36 Company Profiles, Spread across 191 Pages Report Available at http://www.reportsnreports.com/reports/992906-sickle-cell-disease-pipeline-review-h1-2017.html . Sickle Cell Disease - Companies Involved in Therapeutics Development - Acceleron Pharma Inc, Addex Therapeutics Ltd, Addmedica SAS, Advinus Therapeutics Ltd, Alnylam Pharmaceuticals Inc, Angiocrine Bioscience Inc, ArQule Inc, Bio Products Laboratory Ltd, Bioverativ Inc, bluebird bio Inc, Bristol-Myers Squibb Company, Calimmune Inc, CRISPR Therapeutics, CSL Ltd 35,Editas Medicine Inc, Errant Gene Therapeutics LLC, Gamida Cell Ltd, Genethon SA, Gilead Sciences Inc, Global Blood Therapeutics Inc, Incyte Corp, Johnson & Johnson, La Jolla Pharmaceutical Company, MaxCyte Inc, Merck & Co Inc, Modus Therapeutics Holding AB, Morphogenesis Inc, NKT Therapeutics Inc, Novartis AG, Orphagen Pharmaceuticals Inc, Pfizer Inc, Prolong Pharmaceuticals LLC, Protagonist Therapeutics Inc, ReveraGen BioPharma Inc, Sancilio & Company Inc, Sangamo Therapeutics Inc. Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 5, 9, 27, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 2 molecules, respectively. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=992906 Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders). • The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/992906-sickle-cell-disease-pipeline-review-h1-2017.html


News Article | May 9, 2017
Site: globenewswire.com

Support Potential of ADX71441 to treat Irritable Bowel  Syndrome, Interstitial Cystitis and Painful Bladder Syndrome Geneva, Switzerland, 9 May 2017 - Addex Therapeutics (SIX: ADXN) announced today positive results from multiple preclinical studies of ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor, in models of visceral hyperalgesia. The studies were led by Prof. Jyoti N. Sengupta at the Medical College of Wisconsin, with the support of a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the US National Institute of Health. The findings strongly support the potential of ADX71441 in treating hyperalgesia in colonic inflammation (colitis) and bladder inflammation (cystitis). Chronic visceral pain syndromes related to the gastrointestinal or urinary tract represent an important unmet medical need as they can significantly impact the patient's quality of life. "These data represent an important step forward in the understanding of the role played by GABAB receptors in visceral pain and the potential of ADX71441 in large unmet medical needs, such as irritable bowel syndrome, interstitial cystitis and painful bladder syndrome," said Sonia Poli, CSO of Addex. "We look forward to continuing our collaboration with Prof Sengupta's group, and further evaluating the possibility of conducting clinical trials for ADX71441 in these compelling indications." The effect of ADX71441 was studied in reliable, reproducible and quantifiable preclinical models of visceral pain, which included behavioral measurements and electrophysiology recordings(1). Visceral motor reflex after colorectal distension (CRD) and urinary bladder distension (UBD) was significantly decreased (p<0.05) following systemic administration of ADX71441 (5, 10 and 50 mg/kg ip). The visceral analgesic effect of ADX71441 did not affect the normal function of the bladder as assessed by cystometry. In electrophysiology experiments, ADX71441 demonstrated significant inhibition of the response of UBD responsive lumbo-sacral (LS) spinal dorsal horn neurons to graded bladder distension. The effect was observed in spinal intact rats, but not in cervical (C1-C2) spinal transected rats. It also produced a moderate decrease in the spontaneous firing of these neurons in spinal intact rats. ADX71441 had no effect on the mechano-transduction properties or the spontaneous firing of UBD-sensitive pelvic nerve afferent (PNA) fibers. The current behavioral experiments to assess pain and the electrophysiology results indicate that ADX71441 produces visceral analgesia in animal models of cystitis and colitis.  The results indicate that ADX71441 produces this analgesic effect primarily by acting at the supra-spinal sites without affecting bladder motility. "We thank the NIDDK for their support and Prof. Sengupta and his team for their dedication to this important research with ADX71441," commented Tim Dyer, CEO of Addex. "These compelling results are a further example of how we are leveraging our collaborations with leading academic institutions to better understand the potential of the promising candidates in our pipeline." About GABA B receptor The GABAB receptor is clinically & commercially validated. Generic GABAB receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and French health authorities have approved its use for the treatment of alcoholism. Baclofen is also used off label for a number of other indications including overactive bladder (OAB), but its utility is limited due to variety of side effects and rapid clearance, requiring frequent administration of higher doses. About ADX71441 ADX71441 is a potent selective positive allosteric modulator (PAM) which potentiates GABA responses at the GABAB receptor. ADX71441 is a novel, first-in-class, oral, small molecule that demonstrated excellent preclinical efficacy and tolerability in rodent models of pain, anxiety, OAB, alcohol use disorders, nicotine dependence and in a non-human primate model of cocaine use disorder. ADX71441 has also proven efficacy in a genetic model of Charcot-Marie-Tooth Type 1A disease (CMT1A). ADX71441 has a different molecular mechanism from the generic drug baclofen in that it is a positive allosteric modulator, rather than an orthosteric agonist at the GABAB receptor, with a longer half-life, suitable for once daily administration. ADX71441 only acts when the natural ligand (GABA) activates the receptor, therefore respecting the physiological cycle of activation. It has been proposed that PAMs produce less adverse effects and lead to less tolerance than direct agonists. Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase 1 and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM, mGluR7NAM, TrkBPAM and mGluR3NAM & PAM. Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


News Article | May 9, 2017
Site: globenewswire.com

Support Potential of ADX71441 to treat Irritable Bowel  Syndrome, Interstitial Cystitis and Painful Bladder Syndrome Geneva, Switzerland, 9 May 2017 - Addex Therapeutics (SIX: ADXN) announced today positive results from multiple preclinical studies of ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor, in models of visceral hyperalgesia. The studies were led by Prof. Jyoti N. Sengupta at the Medical College of Wisconsin, with the support of a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the US National Institute of Health. The findings strongly support the potential of ADX71441 in treating hyperalgesia in colonic inflammation (colitis) and bladder inflammation (cystitis). Chronic visceral pain syndromes related to the gastrointestinal or urinary tract represent an important unmet medical need as they can significantly impact the patient's quality of life. "These data represent an important step forward in the understanding of the role played by GABAB receptors in visceral pain and the potential of ADX71441 in large unmet medical needs, such as irritable bowel syndrome, interstitial cystitis and painful bladder syndrome," said Sonia Poli, CSO of Addex. "We look forward to continuing our collaboration with Prof Sengupta's group, and further evaluating the possibility of conducting clinical trials for ADX71441 in these compelling indications." The effect of ADX71441 was studied in reliable, reproducible and quantifiable preclinical models of visceral pain, which included behavioral measurements and electrophysiology recordings(1). Visceral motor reflex after colorectal distension (CRD) and urinary bladder distension (UBD) was significantly decreased (p<0.05) following systemic administration of ADX71441 (5, 10 and 50 mg/kg ip). The visceral analgesic effect of ADX71441 did not affect the normal function of the bladder as assessed by cystometry. In electrophysiology experiments, ADX71441 demonstrated significant inhibition of the response of UBD responsive lumbo-sacral (LS) spinal dorsal horn neurons to graded bladder distension. The effect was observed in spinal intact rats, but not in cervical (C1-C2) spinal transected rats. It also produced a moderate decrease in the spontaneous firing of these neurons in spinal intact rats. ADX71441 had no effect on the mechano-transduction properties or the spontaneous firing of UBD-sensitive pelvic nerve afferent (PNA) fibers. The current behavioral experiments to assess pain and the electrophysiology results indicate that ADX71441 produces visceral analgesia in animal models of cystitis and colitis.  The results indicate that ADX71441 produces this analgesic effect primarily by acting at the supra-spinal sites without affecting bladder motility. "We thank the NIDDK for their support and Prof. Sengupta and his team for their dedication to this important research with ADX71441," commented Tim Dyer, CEO of Addex. "These compelling results are a further example of how we are leveraging our collaborations with leading academic institutions to better understand the potential of the promising candidates in our pipeline." About GABA B receptor The GABAB receptor is clinically & commercially validated. Generic GABAB receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and French health authorities have approved its use for the treatment of alcoholism. Baclofen is also used off label for a number of other indications including overactive bladder (OAB), but its utility is limited due to variety of side effects and rapid clearance, requiring frequent administration of higher doses. About ADX71441 ADX71441 is a potent selective positive allosteric modulator (PAM) which potentiates GABA responses at the GABAB receptor. ADX71441 is a novel, first-in-class, oral, small molecule that demonstrated excellent preclinical efficacy and tolerability in rodent models of pain, anxiety, OAB, alcohol use disorders, nicotine dependence and in a non-human primate model of cocaine use disorder. ADX71441 has also proven efficacy in a genetic model of Charcot-Marie-Tooth Type 1A disease (CMT1A). ADX71441 has a different molecular mechanism from the generic drug baclofen in that it is a positive allosteric modulator, rather than an orthosteric agonist at the GABAB receptor, with a longer half-life, suitable for once daily administration. ADX71441 only acts when the natural ligand (GABA) activates the receptor, therefore respecting the physiological cycle of activation. It has been proposed that PAMs produce less adverse effects and lead to less tolerance than direct agonists. Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase 1 and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM, mGluR7NAM, TrkBPAM and mGluR3NAM & PAM. Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


News Article | May 9, 2017
Site: marketersmedia.com

— The Psoriasis market report titled “Psoriasis - Pipeline Review, H1 2017" report provides an overview of Psoriasis clinical trials scenario. Browse the 209 Tables and 10 Figures, 150 Company Profiles, Spread across 648 Pages Report Available at http://www.reportsnreports.com/reports/983978-psoriasis-pipeline-review-h1-2017.html Psoriasis market companies are 3SBio Inc,AbbVie Inc,Abeome Corp,AbGenomics International Inc, Addex Therapeutics Ltd, Adello Biologics LLC, Advinus Therapeutics Ltd, Affibody AB, Albireo Pharma Inc, Alfacyte Ltd, Allergan Plc, Almirall SA, Alteogen Inc, Alvotech Iceland, Amgen Inc, Anacor Pharmaceuticals Inc, AnaptysBio Inc, ApoPharma Inc, Arbor Pharmaceuticals LLC, Arena Pharmaceuticals Inc, Argos Therapeutics Inc, Arrien Pharmaceuticals LLC, AstraZeneca Plc, Athenex Inc, Atlantic Bio Sci LLC, Aurigene Discovery Technologies Ltd, Aurinia Pharmaceuticals Inc, Bayer AG, Beta Pharma Inc, BioApex sro, Biocad, Biocon Ltd, BioLingus AG, BioMAS Ltd, Biomics Biotechnologies Co Ltd,Bionomics Ltd, Bionovis SA, BirchBioMed Inc,Boehringer Ingelheim GmbH,Brickell Biotech Inc,Bristol-Myers Squibb Company,C4X Discovery Holdings PLC,CalciMedica Inc,Can-Fite BioPharma Ltd,Celgene Corp,Cell Medica Ltd,Cellceutix Corp,ChemoCentryx Inc,Chipscreen Biosciences Ltd,ChironWells GmbH,Coherus BioSciences Inc,Compugen Ltd,Concenter BioPharma Silkim Ltd,Crescita Therapeutics Inc,CritiTech Inc,Curapel Ltd,Dermala Inc,Dr. August Wolff GmbH & Co KG Arzneimittle,DURECT Corp,EA Pharma Co Ltd,Eli Lilly and Company,ELORAC Inc,Exicure Inc,Foamix Pharmaceuticals Ltd,Forward Pharma A/S,Galapagos NV,Galderma SA many more.. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=983978 . The Psoriasis market pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology). The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 21, 44, 42, 1, 103, 32 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 6 molecules, respectively. Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Reasons to buy • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/983978-psoriasis-pipeline-review-h1-2017.html

Loading Addex Therapeutics collaborators
Loading Addex Therapeutics collaborators